Abstract
Amyloid fibrils are involved in devastating conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and systemic amyloidosis. They exhibit polymorphism, meaning that a single protein sequence can adopt different amyloid folds that vary with time and self-assembly conditions. Polymorphism confounds structure-based drug design and raises fundamental questions regarding why particular fibril structures form and how they cause disease. Here, we highlight the latest advances in our understanding of amyloid polymorphism, including its structural basis, thermodynamic origins, kinetic influences, and significance for disease. The next frontier will be to predict fibril structures, disentangle the dynamic mechanisms that guide the progression of fibril polymorphs, and illuminate how cofactors and the physiological milieu select for particular polymorphs in disease.